Skip to main content

Andrew Berchuck, MD

Andrew Berchuck, MD
James M. Ingram Professor of Gynecologic Oncology
Campus Mail: 25171 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765
Email: berch001@mc.duke.edu

Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the James M. Ingram Distinguished Professorship. He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers. This includes minimally invasive laparoscopic surgical approaches. He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. He has published over 300 peer-reviewed papers in these areas. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) use of genomic approaches  to elucidate the molecular heterogenetity of ovarian cancer. Thirty fellows and residents have worked in his lab, several of whom are now funded investigators. His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncology and the International Gynecologic Cancer Society. Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006. He has served as editor of several books in the field including Principles and Practice of Gynecologic Oncology. Dr. Berchuck also has a major commitment to national activities, and was President of the Society of Gynecologic Oncology in 2008. He served as chair of the scientific advisory committee of the Ovarian Cancer Research Fund (http://www.ocrf.org) in New York City. Finally, he is also head of the steering committee of the international Ovarian Cancer Association Consortium (OCAC), a group of 50 case-control studies that are working together to identify ovarian cancer susceptibility polymorphisms (www.srl.cam.ac.uk/consortia/ocac/index.html).

Education and Training

  • M.D., Case Western Reserve University, 1980

Research

Dr Berchuck is interested in the molecular pathogenesis of ovarian and endometrial cancer. 

View Publications

Publications

Berchuck, A, Rodriguez, G, Kinney, RB, Soper, JT, Dodge, RK, Clarke-Pearson, DL, and Jr, RCB. "Overexpression of HER-2 neu in endometrial cancer is associated with advanced stage disease." American Journal of Obstetrics and Gynecology 164, no. 1 PART 1 (1991): 15-21.

Scholars@Duke

Berchuck, A, Rodriguez, G, Kinney, RB, Soper, JT, Dodge, RK, Clarke-Pearson, DL, and Bast, RC. "Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease." Am J Obstet Gynecol 164, no. 1 Pt 1 (January 1991): 15-21.

Scholars@Duke

Soper, JT, Berchuck, A, and Clarke-Pearson, DL. "The clinical significance of blood transfusion at the time of radical hysterectomy." Obstet Gynecol 77, no. 1 (January 1991): 165-166. (Letter)

Scholars@Duke

Kohler, MF, Berchuck, A, Baker, ME, Szpak, CA, Soper, JT, and Clarke-Pearson, DL. "Computed tomography-guided fine-needle aspiration of retroperitoneal lymph nodes in gynecologic oncology." Obstet Gynecol 76, no. 4 (October 1990): 612-616.

Scholars@Duke

Soper, JT, Berchuck, A, Olt, GJ, Soisson, AP, Clarke-Pearson, DL, and Bast, RC. "Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma." Am J Obstet Gynecol 163, no. 4 Pt 1 (October 1990): 1204-1209.

Scholars@Duke

SOPER, JT, BERCHUCK, A, OLT, GJ, SOISSON, AP, CLARKEPEARSON, DL, and BAST, RC. "PREOPERATIVE EVALUATION OF SERUM CA-125, TAG-72, AND CA-15-3 IN PATIENTS WITH ENDOMETRIAL CARCINOMA." AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY 163, no. 4 (October 1990): 1204-1209.

Full Text

Hunter, VJ, Daly, L, Helms, M, Soper, JT, Berchuck, A, Clarke-Pearson, DL, and Bast, RC. "The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction." Am J Obstet Gynecol 163, no. 4 Pt 1 (October 1990): 1164-1167.

Scholars@Duke

HUNTER, VJ, DALY, L, HELMS, M, SOPER, JT, BERCHUCK, A, CLARKEPEARSON, DL, and BAST, RC. "THE PROGNOSTIC-SIGNIFICANCE OF CA-125 HALF-LIFE IN PATIENTS WITH OVARIAN-CANCER WHO HAVE RECEIVED PRIMARY CHEMOTHERAPY AFTER SURGICAL CYTOREDUCTION." AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY 163, no. 4 (October 1990): 1164-1167.

Full Text

Berchuck, A, Rodriguez, G, Kamel, A, Soper, JT, Clarke-Pearson, DL, and Bast, RC. "Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina." Obstet Gynecol 76, no. 3 Pt 1 (September 1990): 381-387.

Scholars@Duke

BERCHUCK, A, RODRIGUEZ, G, KAMEL, A, SOPER, JT, CLARKEPEARSON, DL, and BAST, RC. "EXPRESSION OF EPIDERMAL GROWTH-FACTOR RECEPTOR AND HER-2 NEU IN NORMAL AND NEOPLASTIC CERVIX, VULVA, AND VAGINA." OBSTETRICS AND GYNECOLOGY 76, no. 3 (September 1990): 381-387.

Scholars@Duke

Pages